NEJM editorial: blinatumomab as a new standard of care in acute lymphoblastic leukaemia

This is a three-page editorial (Myers and Hunger, New England Journal of Medicine 2026;395:1127-1129), not a report of a study. It accompanies the phase 3 AIEOP-BFM ALL 2017 results published in the same issue and, in its title, calls blinatumomab a new standard of care in acute lymphoblastic leukaemia. The publisher provides neither an abstract nor the full text of the commentary, so we quote none of its reasoning and no figures here; the clinical data it discusses are described in our entry on the trial itself.